TY - JOUR
T1 - Classification, morphology, molecular pathogenesis, and outcome of premalignant lesions of the pancreas
AU - Pittman, Meredith E.
AU - Rao, Rema
AU - Hruban, Ralph H.
N1 - Funding Information:
Accepted for publication May 4, 2017. From the Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York (Drs Pittman and Rao); and the Department of Pathology (Dr Hruban) and the Sol Goldman Pancreatic Cancer Research Center (Dr Hruban), Johns Hopkins University School of Medicine, Baltimore, Maryland. The authors have no relevant financial interest in the products or companies described in this article. This research was supported by NIH grant P50CA62924. Reprints: Meredith E. Pittman, MD, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, Starr 1031A, 525 E 68th St, New York, NY 10065 (email: [email protected]).
PY - 2017/12
Y1 - 2017/12
N2 - Context: Invasive pancreatic ductal adenocarcinoma has a greater than 90% mortality rate at 5 years. Understanding noninvasive, curable precursor lesions gives us the best hope for reducing mortality from pancreatic ductal adenocarcinoma. The 3 pancreatic precursor lesions that have been well studied include intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia. Objective: To give an update on the latest clinical, molecular, and pathologic advances in intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia for the general surgical pathologist. Data Sources: The current literature was analyzed and the authors' experiences with institutional and consult material were incorporated. Conclusions: Our understanding of the molecular alterations that lead from pancreatic precursor lesion to invasive carcinoma continues to evolve. These advances aid clinicians in their treatment decisions and researchers in their search for actionable, druggable targets.
AB - Context: Invasive pancreatic ductal adenocarcinoma has a greater than 90% mortality rate at 5 years. Understanding noninvasive, curable precursor lesions gives us the best hope for reducing mortality from pancreatic ductal adenocarcinoma. The 3 pancreatic precursor lesions that have been well studied include intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia. Objective: To give an update on the latest clinical, molecular, and pathologic advances in intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia for the general surgical pathologist. Data Sources: The current literature was analyzed and the authors' experiences with institutional and consult material were incorporated. Conclusions: Our understanding of the molecular alterations that lead from pancreatic precursor lesion to invasive carcinoma continues to evolve. These advances aid clinicians in their treatment decisions and researchers in their search for actionable, druggable targets.
UR - http://www.scopus.com/inward/record.url?scp=85037060408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037060408&partnerID=8YFLogxK
U2 - 10.5858/arpa.2016-0426-RA
DO - 10.5858/arpa.2016-0426-RA
M3 - Article
C2 - 29189063
AN - SCOPUS:85037060408
SN - 0003-9985
VL - 141
SP - 1606
EP - 1614
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 12
ER -